Single platform femtosecond laser announced at ESCRS

Article

Bausch + Lomb and Technolas Perfect Vision have announced the release of the VICTUS femtosecond laser platform at this year's ESCRS meeting in Vienna, Austria.

Bausch + Lomb (B+L) and Technolas Perfect Vision (TPV) have announced the release of the VICTUS femtosecond laser platform that supports cataract, refractive and therapeutic procedures at this year’s ESCRS meeting in Vienna, Austria.

CEO and president of the Global Surgical Business for B+L, Robert E. Grant, commented on the news, stating, "Our focus is on bringing innovative products, like the VICTUS platform, to the market that uniquely benefit ophthalmic surgeons and patients. TPV's advanced German engineering and precise manufacturing are perfect complements to B+L's surgical portfolio."

The companies have announced that early clinical data on the platform will be presented at the upcoming AAO meeting in Orlando, Florida, USA and at the Asia-Pacific Association of Cataract and Refractive Surgeons in Seoul, South Korea. Additionally, both companies are currently working with regulatory authorities to secure marketing approvals and will promote the platform globally.

This news comes shortly after the recent announcement that B+L and TPV entered into a definitive agreement with an option for B+L to purchase all outstanding and not owned TPV shares.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.